(Q42997693)

English

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

scientific article published in February 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

Ming-Lung Yu

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Chia-Yen Dai

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Zu-Yau Lin

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Li-Po Lee

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Nei-Jen Hou

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ming-Yen Hsieh

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shinn-Cherng Chen

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ming-Yuh Hsieh

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liang-Yen Wang

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wen-Yu Chang

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Wan-Long Chuang

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 February 2006

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Liver International

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

73-81

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Treatment of chronic hepatitis C in southern Taiwan

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

A prospective study on treatment of chronic hepatitis C with tailored and extended interferon-alpha regimens according to pretreatment virological factors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Racial differences in HLA class II associations with hepatitis C virus outcomes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Human leukocyte antigen class I and II alleles and response to interferon-alpha treatment, in Taiwanese patients with chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Prevention of hepatitis C virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2005.01196.X

21 January 2018

Identifiers

10.1111/J.1478-3231.2005.01196.X

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42997693&oldid=1976306163"